JP2017538412A - ヒトｃ−ｍａｆに対する結合メンバー - Google Patents

ヒトｃ−ｍａｆに対する結合メンバー Download PDF

Info

Publication number
JP2017538412A
JP2017538412A JP2017530686A JP2017530686A JP2017538412A JP 2017538412 A JP2017538412 A JP 2017538412A JP 2017530686 A JP2017530686 A JP 2017530686A JP 2017530686 A JP2017530686 A JP 2017530686A JP 2017538412 A JP2017538412 A JP 2017538412A
Authority
JP
Japan
Prior art keywords
seq
sequence
maf
binding member
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017530686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017538412A5 (enExample
Inventor
ロジェル ゴミス，
ロジェル ゴミス，
フアン カルロス テルセロ，
フアン カルロス テルセロ，
Original Assignee
インバイオモーション エセ．エレ．
インバイオモーション エセ．エレ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インバイオモーション エセ．エレ．, インバイオモーション エセ．エレ． filed Critical インバイオモーション エセ．エレ．
Publication of JP2017538412A publication Critical patent/JP2017538412A/ja
Publication of JP2017538412A5 publication Critical patent/JP2017538412A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017530686A 2014-12-11 2015-12-11 ヒトｃ−ｍａｆに対する結合メンバー Pending JP2017538412A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462090599P 2014-12-11 2014-12-11
US62/090,599 2014-12-11
PCT/IB2015/059562 WO2016092524A1 (en) 2014-12-11 2015-12-11 Binding members for human c-maf

Publications (2)

Publication Number Publication Date
JP2017538412A true JP2017538412A (ja) 2017-12-28
JP2017538412A5 JP2017538412A5 (enExample) 2019-01-24

Family

ID=55024191

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017530686A Pending JP2017538412A (ja) 2014-12-11 2015-12-11 ヒトｃ−ｍａｆに対する結合メンバー

Country Status (10)

Country Link
US (1) US10793642B2 (enExample)
EP (1) EP3229909B1 (enExample)
JP (1) JP2017538412A (enExample)
KR (1) KR20170093182A (enExample)
CN (1) CN107001480B (enExample)
AU (1) AU2015358868A1 (enExample)
BR (1) BR112017012515A2 (enExample)
CA (1) CA2967224C (enExample)
MX (1) MX2017007381A (enExample)
WO (1) WO2016092524A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3517630B1 (en) 2010-10-06 2022-01-19 Institució Catalana de Recerca i Estudis Avançats Method for the diagnosis, prognosis and treatment of breast cancer metastasis
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
EP3467124A1 (en) 2012-06-06 2019-04-10 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
KR101872965B1 (ko) 2012-10-12 2018-06-29 인바이오모션 에스.엘. Ｃ―ｍａｆ를 이용하는 전립선암 전이의 진단, 예후 및 치료 방법
CA2903306A1 (en) 2013-03-15 2014-09-18 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the diagnosis, prognosis and treatment of metastatic cancer
KR20170093182A (ko) 2014-12-11 2017-08-14 인바이오모션 에스.엘. 인간 c-maf에 대한 결합 구성원
AU2017271385B2 (en) 2016-05-25 2023-10-05 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-MAF status
MX2020005182A (es) 2017-11-22 2020-08-17 Inbiomotion Sl Tratamiento terapeutico del cancer de mama basado en el estado del c-maf.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013182912A2 (en) * 2012-06-06 2013-12-12 Fundacio Privada Institut De Recerca Biomedica Method for the diagnosis, prognosis and treatment of lung cancer metastasis
WO2014057357A2 (en) * 2012-10-12 2014-04-17 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5185243A (en) 1988-08-25 1993-02-09 Syntex (U.S.A.) Inc. Method for detection of specific nucleic acid sequences
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
GB9509957D0 (en) 1995-05-17 1995-07-12 Khalil Nasreen Post-translational activation of tgf-›1 involving the tsp-1 receptor cd36
US5814468A (en) 1996-03-27 1998-09-29 Coulter International Corp. Methods of enumerating receptor molecules for specific binding partners on formed bodies and in solution
US5958671A (en) 1996-04-23 1999-09-28 Presidents And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
DE69740107D1 (de) 1996-12-23 2011-03-10 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6274338B1 (en) * 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
DK1137941T4 (da) 1998-12-10 2014-01-06 Brystol Myers Squibb Company Protein-scaffolds til antistof-mimetika og andre bindingsproteiner
DE60021254T2 (de) 1999-03-15 2006-04-20 AXYS Pharmaceuticals, Inc., South San Francisco N-cyanomethylamide als protease inhibitoren
DE60132975T2 (de) 2000-01-06 2009-02-26 Merck Frosst Canada Inc., Kirkland Neue substanzen und verbindungen als protease-inhibitoren
EP1272668B1 (en) 2000-04-03 2007-02-14 Corixa Corporation Methods, compositions and kits for the detection and monitoring of breast cancer
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
EP2295081B1 (en) 2001-06-26 2018-10-31 Amgen Inc. Antibodies to OPGL
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
AR036375A1 (es) 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
JP4238138B2 (ja) 2001-12-22 2009-03-11 ４−アンチボディ アーゲー 遺伝的に修飾された脊椎動物前駆体リンパ球の生成方法及び異種結合タンパク質の産生を目的としたその使用。
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
WO2005046731A1 (en) 2003-10-17 2005-05-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Interference with c-maf function in multiple myeloma
WO2005060722A2 (en) 2003-12-18 2005-07-07 President And Fellows Of Hardvard College Modulation of immune system function by modulation of polypeptide arginine methyltransferases
US9134237B2 (en) 2005-09-20 2015-09-15 Janssen Diagnotics, LLC High sensitivity multiparameter method for rare event analysis in a biological sample
CA2623405C (en) 2005-09-20 2014-11-25 Immunivest Corporation Methods and composition to generate unique sequence dna probes labeling of dna probes and the use of these probes
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP2046971B1 (en) 2006-06-30 2012-04-04 University Of Southern California Quantifiable internal reference standards for immunohistochemistry and uses thereof
WO2008086800A2 (en) 2007-01-15 2008-07-24 Aarhus Universitet Predisposition to, prognosis for and treatment of breast cancer relating to human chromosome 16
WO2008098351A1 (en) 2007-02-14 2008-08-21 University Health Network Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
CA2676791A1 (en) 2007-02-16 2008-11-06 Pacific Arrow Limited Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof
CA2687903C (en) 2007-05-24 2016-09-13 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2010003773A1 (en) 2008-06-16 2010-01-14 Siemens Medical Solutions Diagnostics Gmbh Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer
WO2010110346A1 (ja) 2009-03-24 2010-09-30 独立行政法人理化学研究所 白血病幹細胞マーカー
WO2011039734A2 (en) 2009-10-02 2011-04-07 Enzo Medico Use of genes involved in anchorage independence for the optimization of diagnosis and treatment of human cancer
EP3517630B1 (en) 2010-10-06 2022-01-19 Institució Catalana de Recerca i Estudis Avançats Method for the diagnosis, prognosis and treatment of breast cancer metastasis
US20140162887A1 (en) 2011-02-04 2014-06-12 Bioarray Therapeutics, Inc. Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
EP2650682A1 (en) * 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
CA2903306A1 (en) 2013-03-15 2014-09-18 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the diagnosis, prognosis and treatment of metastatic cancer
WO2014184679A2 (en) 2013-03-15 2014-11-20 Inbiomotion S.L. Method for the prognosis and treatment of renal cell carcinoma metastasis
JP6577873B2 (ja) 2013-03-15 2019-09-18 フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） がんの転移の予後診断および処置のための方法
TR201907389T4 (tr) 2013-10-09 2019-06-21 Fundacio Inst De Recerca Biomedica Irb Barcelona Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem.
KR20170093182A (ko) 2014-12-11 2017-08-14 인바이오모션 에스.엘. 인간 c-maf에 대한 결합 구성원
AU2017271385B2 (en) 2016-05-25 2023-10-05 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-MAF status
MX2020005182A (es) 2017-11-22 2020-08-17 Inbiomotion Sl Tratamiento terapeutico del cancer de mama basado en el estado del c-maf.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013182912A2 (en) * 2012-06-06 2013-12-12 Fundacio Privada Institut De Recerca Biomedica Method for the diagnosis, prognosis and treatment of lung cancer metastasis
WO2014057357A2 (en) * 2012-10-12 2014-04-17 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"PURIFIED ANTI-C-MAF ANTIBODY", BIOLEGEND CATALOG / VERSION 1, JPN5017010215, 15 May 2013 (2013-05-15), pages 1 - 3, ISSN: 0004364565 *
J BIOL CHEM, 2002, VOL.277, NO.51, P.49903-49910, JPN6019042645, ISSN: 0004364563 *
PRODUCT CATALOG[ONLINE], C-MAF(M-153):SC-7866, ,<HTTP://DATASHEETS.SCBT.COM/SC-7866.PDF>, [RETRIEVE, JPN6019042646, ISSN: 0004364564 *

Also Published As

Publication number Publication date
CA2967224C (en) 2023-08-22
EP3229909B1 (en) 2020-10-14
BR112017012515A2 (en) 2018-01-02
WO2016092524A1 (en) 2016-06-16
AU2015358868A1 (en) 2017-06-01
EP3229909A1 (en) 2017-10-18
CA2967224A1 (en) 2016-06-16
MX2017007381A (es) 2017-11-06
KR20170093182A (ko) 2017-08-14
US20170369589A1 (en) 2017-12-28
US10793642B2 (en) 2020-10-06
CN107001480A (zh) 2017-08-01
CN107001480B (zh) 2021-12-03

Similar Documents

Publication Publication Date Title
US10793642B2 (en) Binding members for human c-MAF
US20230381209A1 (en) Therapeutic treatment of breast cancer based on c-maf status
CN104788562B (zh) 内皮因子抗体
TR201819859T4 (tr) Akciğer kanseri metastazının tanısı ve prognozu için yöntem.
JP6581572B2 (ja) 補体因子ｈ阻害薬
US20160159888A1 (en) Anti-s100a4 antibody molecules and their uses
TWI911277B (zh) 以結合191p4d12蛋白之抗體藥物結合物(adc)治療癌症之方法
MX2014013931A (es) Metodos para tratar el cancer gastrico.
JP2021531007A (ja) Ｖｉｓｔａに対する受容体
CN120754270A (zh) 用特定抗体药物偶联物与帕博利珠单抗组合治疗癌症
HK40098565A (zh) 基於c-maf状态的乳腺癌治疗性治疗
HK1263074A1 (en) Therapeutic treatment of breast cancer based on c-maf status
HK1263074B (en) Therapeutic treatment of breast cancer based on c-maf status
BR112018074076B1 (pt) Métodos in vitro para projetar uma terapia customizada para um indivíduo que tem câncer de mama e para prever sobrevivência sem doença invasiva

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201012